Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ocugen
< Previous
1
2
3
Next >
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
September 24, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
September 09, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
September 05, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
August 28, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
August 26, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
August 08, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
August 05, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
August 02, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
July 31, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
July 31, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
July 29, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
July 25, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
June 21, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
June 20, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
May 31, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present at BIO International Convention 2024
May 29, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
May 28, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
May 20, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
May 15, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Provides Business Update with First Quarter 2024 Financial Results
May 14, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
May 10, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present at May 2024 Investor Conferences
May 10, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
May 03, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
May 02, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
April 29, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
April 26, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
April 26, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
April 19, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
April 12, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.